Paper Details

  1. Home
  2. Paper Details

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma.

Author: AscariE, BarbaranoL, BergonziC, BrugnatelliS, De PaoliA, DelfiniC, Di StasiM, GiordanoM, MoraO, NicolettiG, PiccininiL, RiccardiA, RinaldiE, SpaneddaR, TinelliC, ValentiniD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined the impact of age on survival in multiple myeloma patients treated with conventional chemotherapy. Younger patients had longer survival times compared to older patients.
Paper Details　
Original Abstract of the Article :
Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy. Between January 1987 and March 1990, 341 consecutive previously untreated patients with multiple myeloma received chemotherapy within the prospective, multicentre, randomized Protocol MM87. Surviva...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/bjc.1998.77

データ提供：米国国立医学図書館（NLM）

Age and Survival in Multiple Myeloma: A Journey Through Cancer Treatment

This study, like a camel caravan venturing into the vast desert of cancer treatment, explores the influence of age on survival outcomes for patients with multiple myeloma. Multiple myeloma is a type of blood cancer affecting plasma cells, and this study analyzes the survival data of a large cohort of patients, seeking to understand the impact of age on treatment response and long-term survival. The researchers delve into the complexities of cancer treatment, seeking to identify factors that influence patient outcomes and improve treatment strategies.

Navigating the Terrain of Cancer Treatment: Age as a Factor

The study reveals a significant association between age and survival outcomes for multiple myeloma patients, highlighting the importance of age as a factor in cancer treatment. It's like navigating a challenging desert landscape, where the terrain and obstacles vary based on the traveler's age and experience. The study's findings underscore the need for individualized treatment plans that consider patient age and other relevant factors, aiming to optimize treatment outcomes and improve survival rates.

A Journey of Hope: Improving Cancer Treatment for All

The study encourages a proactive approach to cancer treatment, emphasizing the importance of considering patient-specific factors to tailor treatment plans and improve outcomes. It's like a camel caravan seeking to find a path to healing in the vast desert of cancer treatment. The research highlights the need for ongoing research and innovation in cancer treatment, striving to improve the lives of patients and offer them hope for a better future.

Dr. Camel's Conclusion

This study, like a guidepost illuminating the path through the desert of cancer treatment, reveals the influence of age on survival outcomes for patients with multiple myeloma. The research highlights the importance of individualized treatment plans and underscores the need for ongoing research and innovation to improve treatment outcomes and enhance the quality of life for cancer patients of all ages.

Date :
  1. Date Completed 1998-02-27
  2. Date Revised 2019-05-15
Further Info :

Pubmed ID

9472648

DOI: Digital Object Identifier

10.1038/bjc.1998.77

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.